## Pharmacy Prior Authorization

## AETNA BETTER HEALTH ILLINOIS (MEDICAID)

Tysabri for Crohn's (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at 1-855-684-5250.

When conditions are met, we will authorize the coverage of Tysabri for Crohn's (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name (please circle	)		
Tysabri (natalizumab)			
Other, please specify			
Quantity	Frequency	Strength _	
Route of Administration	Expected Length of therapy		
Patient Information			
Patient Name:			
Patient ID:			
Patient Group No.:			
Patient DOB:			
Patient Phone:			
Prescribing Physician			
Physician Name:			
Specialty:	NPI Number:		
Physician Fax:	Physician Phone:		
Physician Address:	City, State, Zip:		
Diagnosis:	ICD Code:		
Please circle the appropriate	answer for each question.		
•	orized Tysabri in the past for this patient (i.e., tion is on file under this plan)?	Υ	N
[If no, skip to ques	tion 3.]		
2. Is the patient in reprednisone daily?	mission without requiring more than 5mg of	Υ	N
[No further question	ns.]		
3. Does the patient h	ave a diagnosis of Crohn's Disease?	Υ	N
` .	for the treatment of multiple sclerosis (MS) ed using the MS Agents prior authorization		

Reference Number: C6586-A / Effective Date: 05/08/2017

1

	form.)		
	[If no, then no further questions.]		
4.	Has the patient had inadequate response or intolerable side effects to IV corticosteroids after 7-10 days or oral prednisone (dosed at 40mg or more per day for 30 days)?	Υ	N
	[If yes, skip to question 8.]		
5.	Does the patient have steroid-dependent Crohn's disease as evidenced by one of the following: A) Patient had a relapse within three months of stopping corticosteroids; OR B) Patient is unable to taper steroids to an acceptable dose after 3 months without having symptom recurrence?	Y	N
	[If no, then no further questions.]		
6.	Has the patient had failure to an adequate trial (3 months) of azathioprine (AZA), mercaptopurine (6-mp) or injectable methotrexate?	Y	N
	[If yes, skip to question 8.]		
7.	Does the patient have a contraindication to all of the following: azathioprine (AZA), injectable methotrexate and mercaptopurine (6-mp)?	Y	N
	If yes, please document contraindication(s):		
	[If no, then no further questions]		
8.	Has the patient had a trial and failure of at least one formulary anti-TNF (tumor necrosis factor inhibitor)?	Y	N
	Note: Refer to formulary for covered anti-TNF agents.		
	[If no, then no further questions.]		
9.	Is the patient at least 18 years of age?	Υ	N
	[If no, then no further questions.]		
10	. Is Tysabri being prescribed by, or in consultation with a gastroenterologist?	Y	N
	[If no, then no further questions.]		

Reference Number: C6586-A / Effective Date: 05/08/2017

11. Will Tysabri be given in combination with any antineoplastic, immunosuppressive, or immunomodulating agents (e.g., azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, anti-TNFs?	Y	N		
Comments:				
I affirm that the information given on this form is true and accurate as of this date.				
Prescriber (Or Authorized) Signature	Date			

Reference Number: C6586-A / Effective Date: 05/08/2017